http://www.proactiveinvestors.com.au Proactiveinvestors RSS feed en Thu, 23 Nov 2017 14:42:57 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Zelda Therapeutics' soaring shares attract ASX speeding ticket ]]> http://www.proactiveinvestors.com.au/companies/news/187550/zelda-therapeutics-soaring-shares-attract-asx-speeding-ticket-187550.html Zelda Therapeutics Ltd's (ASX:ZLD) shares are currently in pre-open following the ASX granting the company a trading halt.

Zelda requested the halt pending a response to an ASX price query.

The stock had jumped 24% intra-day to $0.11 before the halt was called.

WATCH NOW: Zelda Therapeutics' Dr Stewart Washer presents at Proactive's CEO Sessions

The halt will remain in place until the opening of trade on Thursday 23rd November 2017, or earlier if an announcement is made to the market.

]]>
Tue, 21 Nov 2017 15:33:00 +1100 http://www.proactiveinvestors.com.au/companies/news/187550/zelda-therapeutics-soaring-shares-attract-asx-speeding-ticket-187550.html
<![CDATA[News - Zelda's Stewart Washer discussed medical cannabis trials with investors at Proactive's CEO Sessions ]]> http://www.proactiveinvestors.com.au/companies/news/187188/zelda-s-stewart-washer-discussed-medical-cannabis-trials-with-investors-at-proactive-s-ceo-sessions-187188.html Zelda Therapeutics Ltd's (ASX:ZLD) executive director, Stewart Washer, joined Proactive's CEO Sessions in Melbourne and Sydney this week.

Zelda is developing a range of cannabinoid-based formulations to treat medical conditions.

WATCH NOW: Zelda Therapeutics' Dr Stewart Washer presents at Proactive's CEO Sessions ACCESS THE FULL PRESENTATION HERE ]]>
Fri, 17 Nov 2017 11:23:00 +1100 http://www.proactiveinvestors.com.au/companies/news/187188/zelda-s-stewart-washer-discussed-medical-cannabis-trials-with-investors-at-proactive-s-ceo-sessions-187188.html
<![CDATA[News - Zelda Therapeutics' shares released from escrow ]]> http://www.proactiveinvestors.com.au/companies/news/187405/zelda-therapeutics-shares-released-from-escrow-187405.html Zelda Therapeutics Ltd (ASX:ZLD) now has an additional 111.6 million shares available for trade on the ASX, following the end of an escrow period.

Zelda now has 530 million shares on issue.

The company is developing a range of cannabinoid-based formulations to treat medical conditions, and Dr. Stewart Washer, executive director, recently presented the next steps to investors.

WATCH NOW: Zelda Therapeutics' Dr Stewart Washer presents at Proactive's CEO Sessions ]]>
Fri, 17 Nov 2017 10:41:00 +1100 http://www.proactiveinvestors.com.au/companies/news/187405/zelda-therapeutics-shares-released-from-escrow-187405.html
<![CDATA[Media files - Zelda Therapeutics' Dr Stewart Washer presents at Proactive's CEO Sessions ]]> http://www.proactiveinvestors.com.au/companies/stocktube/8368/zelda-therapeutics-dr-stewart-washer-presents-at-proactive-s-ceo-sessions-8368.html Wed, 15 Nov 2017 08:30:00 +1100 http://www.proactiveinvestors.com.au/companies/stocktube/8368/zelda-therapeutics-dr-stewart-washer-presents-at-proactive-s-ceo-sessions-8368.html <![CDATA[Media files - Zelda Therapeutics closing in on development of autism clinical trial ]]> http://www.proactiveinvestors.com.au/companies/stocktube/8303/zelda-therapeutics-closing-in-on-development-of-autism-clinical-trial-8303.html Mon, 30 Oct 2017 09:41:00 +1100 http://www.proactiveinvestors.com.au/companies/stocktube/8303/zelda-therapeutics-closing-in-on-development-of-autism-clinical-trial-8303.html <![CDATA[News - Zelda Therapeutics brings medical cannabis trials to Proactive's CEO Sessions ]]> http://www.proactiveinvestors.com.au/companies/news/186138/zelda-therapeutics-brings-medical-cannabis-trials-to-proactive-s-ceo-sessions-186138.html Zelda Therapeutics Ltd (ASX:ZLD) is developing a range of cannabinoid-based formulations to treat medical conditions, and recently sponsored an observation autism trial in Chile.

The trial demonstrated successful results for treating the core symptoms of autism with medicinal cannabis extracts that Zelda is planning on taking into clinical trials.

Results showed that in a cohort of 21 patients, cannabis extracts were significantly more effective than conventional medicines used, including atypical antipsychotics, and these extracts were well tolerated by the patients overall.

Find out more from Dr. Stewart Washer at Proactive's CEO Sessions.

Click below to register by email

- Melbourne: Tuesday 14th November.
- Sydney: Wednesday 15th November.
- Email Pauline here.
- Call office on (02) 9280 0700.

Presenter list

- Zelda Therapeutics (ASX:ZLD): Dr. Stewart Washer
- Thred Ltd (ASX:THD): Geoff Marshall
- De Grey Mining (ASX:DEG): Simon Lill
- Peninsula Energy (ASX:PEN): David Coyle
- Aspire Mining (ASX:AKM): David Paull

 

]]>
Fri, 27 Oct 2017 08:38:00 +1100 http://www.proactiveinvestors.com.au/companies/news/186138/zelda-therapeutics-brings-medical-cannabis-trials-to-proactive-s-ceo-sessions-186138.html
<![CDATA[News - Zelda Therapeutics demonstrates successful results treating autism with medicinal cannabis ]]> http://www.proactiveinvestors.com.au/companies/news/184098/zelda-therapeutics-demonstrates-successful-results-treating-autism-with-medicinal-cannabis-184098.html Zelda Therapeutics Ltd (ASX:ZLD) has sponsored an observation autism trial in Chile, demonstrating successful results for treating the core symptoms of autism with medicinal cannabis extracts that Zelda is planning on taking into clinical trials.

The results demonstrated that in a cohort of 21 patients (median age of 9 years 10 months), cannabis extracts were significantly more effective than conventional medicines used, including atypical antipsychotics, and these extracts were well tolerated by the patients overall.

Harry Karelis, executive chairman for Zelda, commented:

"The results from this observational study are very exciting and supports the anecdotal evidence we have, showing the positive effect medicinal cannabis has on treating autism symptoms.

"Zelda will use this baseline data to design its clinical trials and generate rigorous scientific data that validates the clinical benefit of medicinal cannabis.

"We hope that in the near future Zelda Therapeutics can provide an alternative treatment for sufferers of this condition which is of major global significance."

Details of the study

Patients in the study were treated over at least a 12-week period and were examined by electroencephalogram (EEG), neuropsychological analysis as well as metabolism and genetic tests.

The patients in the study had not responded well to conventional treatments.

Patients treated with cannabis extracts demonstrated significant improvements in at least one core symptom including social interaction, language or repetitive behaviours in 71.4% of cases and 66.7% of treated patients showing significant general overall improvement. 

The trial was managed by leading clinician Dr Gisela Kuester who is a highly regarded neurologist specialising in the diagnosis and treatment of autism.

She also holds the position of Clinical Research Director at Fundación Daya.

Strategic alliance

Zelda has previously outlined its strategic alliance with Chilean non-profit patient advocate group Fundación Daya, to leverage their patient data on using cannabinoid-based therapy to treat autism patients.

The results from this observation trial will assist Zelda in the development of its autism clinical trial.

A submission for ethics approval is being finalized and is expected to be submitted in coming weeks.

Zelda expects the trial will commence within three months of regulatory approvals being obtained and will be conducted over a six to nine-month period.

]]>
Mon, 18 Sep 2017 09:48:00 +1000 http://www.proactiveinvestors.com.au/companies/news/184098/zelda-therapeutics-demonstrates-successful-results-treating-autism-with-medicinal-cannabis-184098.html
<![CDATA[News - Zelda Therapeutics making strides in medical cannabis research ]]> http://www.proactiveinvestors.com.au/companies/news/183867/zelda-therapeutics-making-strides-in-medical-cannabis-research-183867.html Zelda Therapeutics Ltd (ASX:ZLD) is making significant progress with its medical cannabis research program in Chile.

The company has already established a focus on autism, eczema and insomnia.

Zelda has now engaged the services of an experienced team of clinicians and scientists to help manage its clinical trials.

Harry Karelis, executive chairman, commented:

"We welcome Dr Kuester, Dr Sasso and Ms Vergara to our research team and are delighted to have such a high calibre local team coordinating our activities in Chile.

"Zelda is steadily progressing towards commencement of its clinical trial program in Chile and I look forward to providing shareholders positive updates in due course."

Why Chile

Zelda has strategically focused on conducting its research activities in Chile due to the efficiency of its legal and regulatory framework, cost effectiveness and its market access into the large South American pharmaceutical market.

The Chilean government granted permission for the first cannabis crop to be planted for medicinal purposes in 2015, and has subsequently allowed the sale of medicinal cannabis in pharmacies.

This has given rise to researchers and organisations specialising in medicinal cannabis treatments.

Zelda has capitalised on this, forming strategic alliances with world-class researchers and physicians, and has access to valuable patient data which will assist in the development of robust clinical trials.

]]>
Wed, 13 Sep 2017 08:58:00 +1000 http://www.proactiveinvestors.com.au/companies/news/183867/zelda-therapeutics-making-strides-in-medical-cannabis-research-183867.html
<![CDATA[News - Zelda shareholders granted priority on float of CannPal Animal Therapeutics ]]> http://www.proactiveinvestors.com.au/companies/news/183056/zelda-shareholders-granted-priority-on-float-of-cannpal-animal-therapeutics-183056.html Zelda Therapeutics Ltd (ASX:ZLD) has a strategic collaborative partnership with CannPal Animal Therapeutics, which is in the process of listing on the ASX.

The companies are looking to exploit opportunities of mutual interest in both the human and animal pharmaceutical markets through the sharing of research data compiled by each of the parties.

CannPal is looking to strengthen the ties between the companies by inviting Zelda shareholders to participate as a priority applicant in the prospectus capital raising lodged with ASIC.

The prospectus is to raise $6 million.

Prospectus and offer details

Under the prospectus, 5 million shares at $0.20 have been allocated and made available to Zelda shareholders registered on the 1st September 2017 holding a minimum of 25,000 shares.

The minimum subscription in CannPal is 10,000 shares worth $2,000.

]]>
Tue, 29 Aug 2017 11:23:00 +1000 http://www.proactiveinvestors.com.au/companies/news/183056/zelda-shareholders-granted-priority-on-float-of-cannpal-animal-therapeutics-183056.html
<![CDATA[News - Zelda Therapeutics' Dr. Stewart Washer discusses medical cannabis achievements ]]> http://www.proactiveinvestors.com.au/companies/news/183050/zelda-therapeutics-dr-stewart-washer-discusses-medical-cannabis-achievements-183050.html Zelda Therapeutics Ltd (ASX: ZLD) has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols.

This human data has been generated over several years by a California-based group (Aunt Zelda’s) that has a high profile within the U.S. which is also growing internationally.

The company has a deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has embarked on a program of human clinical trials.

WATCH NOW: Zelda half-year review by Stewart Washer, executive director

Zelda is scheduled to release its financial statements to the ASX on Wednesday 30 August 2017.

]]>
Tue, 29 Aug 2017 09:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/183050/zelda-therapeutics-dr-stewart-washer-discusses-medical-cannabis-achievements-183050.html
<![CDATA[News - Zelda Therapeutics expands breast cancer research ]]> http://www.proactiveinvestors.com.au/companies/news/181672/zelda-therapeutics-expands-breast-cancer-research-181672.html Zelda Therapeutics (ASX:ZLD) has expanded its research collaboration with Complutense University, based on positive initial research results from its breast cancer research program.

The program builds on positive results from its initial proof of concept study from 2016 and follow-on studies in 2017 on its pre-clinical research on cannabinoids as anti-cancer agents.

Results showed a number of key findings, but most importantly that there were anti-cancer effects observed across a range of different breast cancer cell lines using Zelda’s formulations.

Harry Karelis, chairman, commented: “We are delighted to be in a position to expand our research collaboration with Complutense University, who have already generated exciting results using Zelda formulations on breast cancers.

“Expanding our research to gain a deeper understanding of the impact of cannabinoids on tumour re-occurrence is a critical area of research to be able to develop effective anti-cancer therapies in future.”

Expansion of research program

The expansion and extension of Zelda’s current research program with Complutense University will investigate the effect of cannabinoids on cancer stem cell-like cells.

These cells are cancer cells found within tumours that are self-renewing, causing tumour re-growths.

Tumour reoccurrence is a common concern for women following treatment of breast cancer.

The majority of current anticancer therapies are primarily focused on trying to inhibit cancer cell growth, causing cancer cells to die, or a combination of both.

However, even if initial treatments appear successful, some tumours can reoccur at a later date.

The role that cannabinoids can play

Understanding how tumours re-occur and what controls the ability of cancer cells to spread throughout the body, is a crucial aspect of cancer research.

Furthermore, investigating the impacts that cannabinoids could have on cancer stem-cell like cells could provide much needed data in this area of research, and most importantly lead to new treatment regimes for highly resistant tumours.

How this fits into the bigger picture

With positive data already at hand and expansion into further research areas, Zelda continues to make progress on its preclinical activities, in-line with its strategic plan.

Zelda is focused on developing high-quality data packs and an intellectual property portfolio expected to be of great interest to the biopharmaceutical industry and potential future partnering deals.

]]>
Mon, 31 Jul 2017 14:09:00 +1000 http://www.proactiveinvestors.com.au/companies/news/181672/zelda-therapeutics-expands-breast-cancer-research-181672.html
<![CDATA[News - Zelda Therapeutics enters manufacturing and distribution agreement ]]> http://www.proactiveinvestors.com.au/companies/news/179273/zelda-therapeutics-enters-manufacturing-and-distribution-agreement-179273.html Zelda Therapeutics (ASX:ZLD) has entered into a strategic manufacturing and distribution agreement with leading Chilean pharmaceutical manufacturing group, Knop Laboratorios SA.

The agreement locks in a high-quality supply of Zelda’s formulated medicinal-cannabis medicines initially, for its planned clinical trials, and subsequently a secure, scalable and GMP-grade source of commercial quantities following product registration.

Furthermore, Knop operates a chain of pharmacies throughout Chile and the agreement contemplates Knop becoming a key distribution channel in the future for Zelda.

Harry Karelis, chairman, commented: “We are delighted to be entering into this partnership with Knop who have an impressive history in Chile and extensive relationships with key regulators.

“They operate a world-class facility with a newly commissioned ethanol-extraction facility dedicated to producing high-quality cannabis-derived extracts.“


Knop Laboratories

Knop Laboratories are recognised as a signature trusted brand in Chile, dating back to the 1920s.

Knop’s related companies include a pharmacy chain which spans across Chile.

This organisational structure makes Knop an ideal partner for the manufacture of Zelda’s products, providing access to a large distribution network to fast track market penetration in South America.

Zelda has chosen to expand its research programme into Chile because the country’s legal framework recognises the importance of medical cannabis, allowing its production under strict regulatory controls for the treatment of medical conditions.

The country also provides a cost-effective location for Zelda to conduct clinical trials.


Background

Zelda is bio-pharmaceutical company focused on a series of clinical and pre-clinical programs utilising cannabinoid-based medicines.

Zelda has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols.

This human data has been generated over several years by a California-based group that has a high profile within the U.S. and a growing international profile.

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia), autism and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.

 

Analysis

The partnership provides a solid platform to expand the company’s activities including its focus on rapid commercialisation.

It will allow Zelda to expedite the clinical trial process, with the certainty of product supply.

Furthermore, it will potentially allow the mass production of Zelda’s medicines for the treatment of eczema, insomnia and autism, providing a natural alternative to many patients who suffer from these conditions.

Knop sees the rapidly growing medicinal cannabis market as a key opportunity and the partnership as a pathway to global opportunities.

Knop believes that Australia and Chile are both well placed to secure leading positions in the global medicinal cannabis market and help fast-track high quality, affordable medicines to patients in need.

Zelda shares have more than doubled in 2017, currently priced at $0.083.

]]>
Thu, 15 Jun 2017 10:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/179273/zelda-therapeutics-enters-manufacturing-and-distribution-agreement-179273.html
<![CDATA[News - Zelda Therapeutics builds upon breast cancer research ]]> http://www.proactiveinvestors.com.au/companies/news/178675/zelda-therapeutics-builds-upon-breast-cancer-research-178675.html Zelda Therapeutics (ASX:ZLD) has received positive results from its ongoing pre-clinical research into the effects of cannabinoids against various types of human breast cancers.

These latest results from a series of in-vitro studies confirms statistically significant anti-cancer effects across a range of different breast cancer cell lines using medicinal cannabis oils.

Studies are ongoing with further data expected in coming months from additional in-vitro and in-vivo studies that are currently underway.

Harry Karelis, chairman, commented: “We are very excited by the continued positive data being generated by our studies.

“We continue to develop our knowledge in this important clinical area and believe there is growing evidence to consider cannabinoids as part of the future treatment regimes for breast cancer particularly for Triple Negative tumours that currently have limited treatment options.”


Pre-clinical research details

These latest experiments follow on from initial results announced in November 2016 which showed:

- Specific formulations of THC-rich oil was significantly more potent at reducing HER2+ breast tumour growth than pure THC; and
- Was equally as potent as breast cancer drug Lapatanib in reducing tumour growth in mice hosting HER2+ human tumours.

The new results demonstrate the potential for cannabinoid-based therapies to be therapeutically beneficial in a broad spectrum of breast cancer types including hormone receptor positive, HER2+ and Triple Negative cancer types.

Significantly, the Zelda THC-rich formulation showed significantly greater anti-cancer effect than pure synthetic THC suggesting that full extracts have greater efficacy than pure compounds.

This effect was consistent across all cancer sub-types suggesting a novel mechanism of action that could form the basis for the development for future therapies.

These results were generated by world leading cannabis cancer researchers at Complutense University of Madrid, led by Professor Cristina Sánchez and Professor Manuel Guzmán.


Analysis

Triple Negative breast cancers, constitute circa 15% of breast cancers and are the most aggressive type.

With chemotherapy, radiation and surgery being the only options, there is significant market demand for new treatments to increase survival rates.

While there is a long way to go before this approach reaches formal human clinical trials, this data importantly supports the anecdotal experiences already seen in patients in California.

Furthermore, the results provide additional evidence that strongly points in favour of using whole-plant extracts over single cannabinoid molecules.

Zelda shares are trading up over 40% year to date, currently priced at $0.056.

]]>
Fri, 02 Jun 2017 12:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/178675/zelda-therapeutics-builds-upon-breast-cancer-research-178675.html
<![CDATA[Media files - Zelda Therapeutics expands medical cannabis clinical trials ]]> http://www.proactiveinvestors.com.au/companies/stocktube/7411/zelda-therapeutics-expands-medical-cannabis-clinical-trials-7411.html Tue, 09 May 2017 08:00:00 +1000 http://www.proactiveinvestors.com.au/companies/stocktube/7411/zelda-therapeutics-expands-medical-cannabis-clinical-trials-7411.html <![CDATA[News - Zelda Therapeutics expands medical cannabis clinical trial ]]> http://www.proactiveinvestors.com.au/companies/news/176563/zelda-therapeutics-expands-medical-cannabis-clinical-trial-176563.html Zelda Therapeutics (ASX:ZLD) has expanded its medical cannabis clinical trial program in Chile to include autism, which is expected to commence in the second half of 2017.

Autism is a lifelong development disability characterized by impairments in social communication and interactions.

The global market for autism diagnosis and treatments is expected to grow to US$412.7 million by 2019.

Zelda will work together with Chilean non-profit patient advocate group Fundación Daya, leveraging their clinical experiences with autism patients.

Harry Karelis, executive chairman, commented: “Our investment into conducting a rigorous and controlled clinical trial paves the way for product registrations next year significantly improving patient access to a novel form of treatment.

“Our intention would be to replicate this trial in other key jurisdictions to rapidly improve patient access in other jurisdictions.”


Chile’s advantage

The legal framework in Chile recognises the importance of medical cannabis, allowing its production under strict regulatory controls for the treatment of medical conditions.

The country also provides a cost-effective location for Zelda to conduct clinical trials.

Furthermore, Zelda through its relationship with AusCann Group Holdings (ASX:AC8) will leverage Auscann’s Chilean joint-venture DayaCann to supply high quality medical cannabis for the autism trial.

Fundación Daya has extensive experience over a number of years in using medical cannabis to treat patients diagnosed with autism.

This clinical experience demonstrates solid anecdotal evidence of positive quality of life outcomes using cannabinoid-based therapy.


Trial details

Subject to regulatory approvals being obtained, Zelda expects the trial will commence in the second half of 2017, with trial protocols already being developed.

Zelda expects the trial to be conducted over a period of 3-6 months.


Well-funded pathway to revenue

Zelda’s recent $6.0 million capital raising provides it with increased flexibility to pursue new opportunities and diversify such as this.

Successful results will allow Zelda to immediately commence the product registration process to sell clinically approved products in the Chilean market.

This provides a clear pathway to potential revenue generation from Chile and other South American markets as early as 2018.

]]>
Wed, 19 Apr 2017 13:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/176563/zelda-therapeutics-expands-medical-cannabis-clinical-trial-176563.html
<![CDATA[News - Zelda Therapeutics completes successful share placement ]]> http://www.proactiveinvestors.com.au/companies/news/175640/zelda-therapeutics-completes-successful-share-placement-175640.html Zelda Therapeutics (ASX:ZLD) has successfully raised $6 million through the placement of 85.7 million shares to sophisticated and professional investors priced at $0.07.

The capital raising was significantly oversubscribed with strong support from new Australasian institutional investors.

Funds will be used to accelerate and expand research and clinical programs.

The placement will increase the company’s cash position to circa $8.3 million before costs.

This provides sufficient financial capacity for Zelda to execute its current research programs and pursue new opportunities to grow its clinical pipeline for the development of new medicinal cannabis therapies in Australia and Chile.

In-line with the company’s business strategy, Zelda is focused on delivering world-class research to clinically prove the benefits of medical cannabis for specific disease targets, with a clear commercialisation pathway to drive maximum shareholder value.

Zelda shares are trading up 145% year to date, currently priced at $0.096.

]]>
Thu, 30 Mar 2017 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/175640/zelda-therapeutics-completes-successful-share-placement-175640.html
<![CDATA[News - Zelda Therapeutics to increase cash position ]]> http://www.proactiveinvestors.com.au/companies/news/175482/zelda-therapeutics-to-increase-cash-position-175482.html Zelda Therapeutics (ASX:ZLD) has been granted a trading halt by the ASX, pending details of a capital raising.

The halt will remain in place until the opening of trade on Thursday 30th March 2017, or earlier if an announcement is made to the market.

]]>
Tue, 28 Mar 2017 10:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/175482/zelda-therapeutics-to-increase-cash-position-175482.html
<![CDATA[News - Zelda Therapeutics embraces opportunities in the animal health market ]]> http://www.proactiveinvestors.com.au/companies/news/175406/zelda-therapeutics-embraces-opportunities-in-the-animal-health-market-175406.html Zelda Therapeutics (ASX:ZLD) has been an ASX-outperformer in recent months, as the company continues to receive a positive re-rating on the back of milestones.

Zelda has today executed a binding term sheet with CannPal Pty Ltd to assist in the development of opportunities in the animal health market utilising cannabinoid-based treatments.

CannPal is an Australian company focused on developing cannabis based prescription and non-prescription medicines.

The company also is also targeting animal feed nutrition for the emerging global pet pharmaceutical market.


Importance of the deal

The term sheet allows Zelda to be granted the first rights for human applications over any data generated in CannPal’s veterinary trials.

This directly increases Zelda’s treatment pipeline.

Zelda will also be granted options over 10% of CannPal. CannPal is aiming to list on the ASX in the latter part of 2017.

Harry Karelis, executive chairman for Zelda, commented that the CannPal partnership outsources Zelda’s animal studies, while retaining the company's focus on human studies for a zero cost.

"It also provides Zelda with exposure to pet pharmaceuticals, a whole new market segment which is growing at rapid pace."


Analysis

Zelda's strategic purpose is moving towards the production of cannabis based therapies for humans.

This new agreement provides further opportunity to potentially expand the company's current research focus areas while opening doors to capitalise on the pet pharmaceutical market.

Investors have embraced Zelda's strategy and ability to continually deliver on milestones.

Zelda is trading 13.3% higher in morning trade at $0.094 per share.

In late 2016 when the company completed re-compliance and listed back on the ASX, shares in the raising could have been snapped up for just $0.025 per share.

]]>
Mon, 27 Mar 2017 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/175406/zelda-therapeutics-embraces-opportunities-in-the-animal-health-market-175406.html
<![CDATA[News - Zelda Therapeutics plans medical cannabis trials in Chile this year ]]> http://www.proactiveinvestors.com.au/companies/news/175253/zelda-therapeutics-plans-medical-cannabis-trials-in-chile-this-year-175253.html Zelda Therapeutics (ASX:ZLD) has expanded its clinical trial program to include two new trials to begin in the second half of CY2017 in Chile.

The trials will target insomnia and eczema, two significantly sized markets with combined global value of circa $8 billion in 2016.

Zelda intends to register products for sale in Chile should trials be successful providing a pathway to maiden revenues.

Harry Karelis, chairman, commented: “The sleep and dermatitis markets represent significant opportunities for Zelda Therapeutics.

“The proposed clinical trials in Chile will complement our other trial and pre-clinical research activities.”


Advantages of Chile

Chile provides a cost-effective location for Zelda to conduct clinical trials.

Chile has made significant progress in its legal framework to recognize the importance of medical cannabis research, allowing the production of medical cannabis under strict regulatory controls for the treatment of medical conditions, since 2014.

Zelda has identified key clinicians and sites within Chile where the trials will take place, with clinical trial protocols being finalised for submission to the relevant human ethics committees for approval.


Relationship with AusCann Group Holdings (ASX:AC8)

To streamline the Chilean clinical trials and facilitate the research program, Zelda will leverage its relationship with AusCann through its Chilean joint-venture DayaCann and will also work together with Chilean non-profit patient advocate group Fundacion Daya.

DayaCann is the only licensed producer of medicinal cannabis in Chile and is expected to harvest its first crop in the second quarter of CY2017.


Analysis

These trials provide a valuable opportunity and potential pathway to revenue for Zelda.

The company expects to conclude the trials by the end of CY2017 with data available shortly thereafter.

The product registration process will then commence allowing Zelda to sell clinically approved products as soon as positive trial data is in hand.

This provides a pathway to potential revenue generation as early as 2018.

Zelda shares have continued their strong run in 2017 trading up over 100% year to date to $0.082.

This also means that the medical cannabis company’s share price has more than tripled since listing via reverse takeover on the Australian Stock Exchange in November, 2016 at $0.025.

]]>
Thu, 23 Mar 2017 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/175253/zelda-therapeutics-plans-medical-cannabis-trials-in-chile-this-year-175253.html
<![CDATA[News - Zelda Therapeutics expands pipeline of opportunities ]]> http://www.proactiveinvestors.com.au/companies/news/175112/zelda-therapeutics-expands-pipeline-of-opportunities-175112.html Zelda Therapeutics (ASX:ZLD) continues to leverage world-class knowledge and expertise in the medical cannabis sector.

A new license agreement with Caziwell Inc increases flexibility to expand the clinical trial program.

The agreement provides significant immediate and long-term financial benefits for Zelda and replaces the existing agreement.

Harry Karelis, executive chairman for Zelda, commented:

“The restructuring of the Caziwell Licence Agreement provides a meaningful positive impact to Zelda shareholders by reducing future financial obligations it would have incurred through executing its clinical trials strategy.

"With these amendments in place, Zelda moves closer to industry standards for agreements of this nature.

"We have a full pipeline of opportunities ahead of us and reducing future expenses helps extend our financial capacity to progress these projects.

"We have a very exciting year ahead."


New license agreement benefits

- Zelda maintains exclusive access to patient data, formulations and protocols for use in its current research activities;
- Positive impact on cashflow, with an immediate $200,000 saving;
- Permanent reduction in future royalty and sub-licence fees; and
- Significantly increases flexibility to expand clinical trial program.


Trials

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.


World-leading Scientific Advisory Board

Prof. Manuel Guzman: Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death.

Dr Cristina Sanchez: Assistant Professor at Complutense University, Madrid Spain. Specialist in the area of lipid signaling, including cannabinoids in an oncology setting.

Dr Joe Goldstrich: Distinguished clinical career in preventive cardiology and nutrition spanning over 40 years. He has evaluated over 3,500 patients in the US using cannabis as a fundamental medicine in the management of a variety of medical conditions.

Dr Noah Federman: Highly respected paediatric clinical and research oncologist. Currently, Director of the Paediatric Bone and Soft Tissue Sarcoma Program at University of California, part of the prestigious UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Centre.


Analysis

Zelda continues to expand its relationships and agreements in the sector.

The company has a strong background in medical cannabis, and was formed to fund clinical efficacy trials developed by its U.S. partner, Aunt Zelda, and used to treat a range of diseases showing strong efficacy data.

Investors are recognising the potential since the listing (via RTO) in November 2016, where shares could be purchased at $0.025 in the $4 million raising.

Since then Zelda has more than tripled in value, last trading at $0.085 per share.

]]>
Tue, 21 Mar 2017 14:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/175112/zelda-therapeutics-expands-pipeline-of-opportunities-175112.html
<![CDATA[News - Zelda Therapeutics trade higher on medical cannabis focus ]]> http://www.proactiveinvestors.com.au/companies/news/175021/zelda-therapeutics-trade-higher-on-medical-cannabis-focus-175021.html Zelda Therapeutics (ASX:ZLD) shares have continued their strong run in 2017 trading up over 85% year to date to $0.074.

This also means that the medical cannabis company’s share price has nearly tripled since listing on the Australian Stock Exchange in November, 2016 at $0.025.

Zelda is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.

This human data has been generated over several years by a California-based group that has a high profile within the U.S. and a growing international profile.

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.

The company expects to be commencing these trials during 2017 and have identified a relatively rapid path to commercialisation.

If successful, this could see Zelda obtaining product registrations in selected markets in 2018 with revenues flowing from there.

]]>
Mon, 20 Mar 2017 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/175021/zelda-therapeutics-trade-higher-on-medical-cannabis-focus-175021.html
<![CDATA[News - Zelda Therapeutics to offer share sale facility ]]> http://www.proactiveinvestors.com.au/companies/news/171912/zelda-therapeutics-to-offer-share-sale-facility-171912.html The facility is open to any holder with 15,151 shares of less, at a fixed price of $0.033 per share.

This represents 1,936,134 shares held by 891 shareholders.


Medicinal cannabis

Zelda has a focus on medicinal cannabis biotechnology, and all of the company's research and clinical programs are fully funded and benefit from the Australian Government R&D tax rebate program.

This provides non-dilutive funding for the company.


Analysis

Zelda has identified several indications (medical disease areas) where it can fast-track formulations into human clinical trials – notably sleep disorders such as insomnia and dermatology indications such as eczema.

The company expects to be commencing these trials during 2017 and have identified a relatively rapid path to commercialisation.

If successful, this could see Zelda obtaining product registrations in selected markets in 2018 with revenues flowing from there.

]]>
Fri, 20 Jan 2017 09:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/171912/zelda-therapeutics-to-offer-share-sale-facility-171912.html
<![CDATA[News - Zelda Therapeutics shares gain 60% since listing on medicinal cannabis focus ]]> http://www.proactiveinvestors.com.au/companies/news/171287/zelda-therapeutics-shares-gain-60-since-listing-on-medicinal-cannabis-focus-171287.html The company has a solid pipeline of news and achievements pending for 2017.

Zelda is implementing a two-pronged strategy to develop Zelda into a leading medicinal cannabis biotechnology company.

This approach provides a pathway to revenues in the short term through fast-tracked clinical trials, whilst generating potential value in the background through its cancer research activities.


Research and clinical programs

Importantly, all of the company's research and clinical programs are fully funded and benefit from the Australian Government R&D tax rebate program providing non-dilutive funding for the company.


Analysis

Zelda has identified several indications (medical disease areas) where it can fast-track formulations into human clinical trials – notably sleep disorders such as insomnia and dermatology indications such as eczema.

The company expects to be commencing these trials during 2017 and have identified a relatively rapid path to commercialisation.

If successful, this could see Zelda obtaining product registrations in selected markets in 2018 with revenues flowing from there.

]]>
Mon, 09 Jan 2017 09:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/171287/zelda-therapeutics-shares-gain-60-since-listing-on-medicinal-cannabis-focus-171287.html
<![CDATA[News - Zelda Therapeutics teams with Curtin University ]]> http://www.proactiveinvestors.com.au/companies/news/170710/zelda-therapeutics-teams-with-curtin-university-170710.html Research is expected to commence in early 2017.

The collaboration will test a range of Zelda’s formulations and protocols against Curtin’s suite of in vitro pancreatic cancer models.

This is where the cannabis formulations will be tested against human pancreatic cell cancer lines grown in the laboratory.

Harry Karelis, executive chairman for Zelda, commented: "The pancreatic cancer market is an important market for many reasons.

"Not only is it one of the most common cancers but the survival rates are astoundingly low and we at Zelda are hopeful of demonstrating anti-cancer activity in this area.

"This collaboration builds on the existing partnership with Professor Manuel Guzmán and Professor Cristina Sánchez at Complutense University, who are both considered the leaders in the field of anti-cancer effects of cannabinoids.

"Positive results from this work will lay the foundation for progression into further anti-cancer studies and is expected to generate new intellectual property for the company."

]]>
Tue, 20 Dec 2016 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/170710/zelda-therapeutics-teams-with-curtin-university-170710.html
<![CDATA[News - Zelda Therapeutics outlines strategy as shares continue to climb ]]> http://www.proactiveinvestors.com.au/companies/news/170299/zelda-therapeutics-outlines-strategy-as-shares-continue-to-climb-170299.html Zelda Therapeutics (ASX:ZLD) continues to garner strong investor support, following its recent transition into the medical cannabis, following a reverse takeover.

As part of the re-listing, Zelda raised $4 million at $0.025.

Zelda has been re-rated in recent weeks as the company continues to deliver on milestones.

Today the stock is trading 5.3% higher at $0.04 after outlining its strategy to target the significant sleep disorder market.

The company has identified trial sites in multiple target locations, including the U.S. and Australia.

Zelda is also progressing discussions with potential partner Clinical Research Organisations (CROs) in local markets and submissions for the necessary approvals from the relevant ethics committees in each location are now in progress.

The company anticipates receiving approvals early next year with the trials able to commence shortly thereafter in 2017.


Market opportunity

Harry Karelis, executive chairman, commented: "The sleep disorder market represents a significant opportunity for medical cannabis treatments.

"We believe that consumers are looking for safe, effective, affordable alternatives to current prescription medication.

"Our exclusive access to Aunt Zelda’s patient data has provided us with the ability to trial a formula that already has existing evidence and data to demonstrate its
efficacy in this particular disorder.

"The purpose of these trials is to establish robust, clinical evidence and to create a comprehensive data pack that can be used to progress later stage trials and/or seek product registrations in certain markets and generate product sales in the
medium term."


Market size

Insomnia is estimated to impact approximately 35% of the global population and is considered to be a prime factor for chronic disability in the workforce.

The global sleep aids market was valued at US$58.1 billion in 2014 and is expected to expand to reach US$80.8 billion by 2020, according to the research firm Persistence Market Research.

Sleep aids are drugs and medical devices that help a person to fall asleep.


The making of Zelda

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.

]]>
Mon, 12 Dec 2016 14:10:00 +1100 http://www.proactiveinvestors.com.au/companies/news/170299/zelda-therapeutics-outlines-strategy-as-shares-continue-to-climb-170299.html
<![CDATA[News - Zelda Therapeutics to work with a leading medical research institute ]]> http://www.proactiveinvestors.com.au/companies/news/169926/zelda-therapeutics-to-work-with-a-leading-medical-research-institute-169926.html Zelda Therapeutics (ASX:ZLD) has entered into a collaboration agreement with the highly regarded, Perth-based Telethon Kids Institute.

This collaboration will initially focus on pre-clinical testing of Zelda’s compounds, formulations and protocols in the area of children’s brain cancer.

Zelda was spun out of a successful U.S. based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.


Collaboration

The collaboration with the Telethon Kids Institute will be confined to pre-clinical research accessing the Institute’s validated cell and animal models for the studies.

Through the research, the Institute will examine the potential for Zelda’s compounds to act as anti-cancer agents, either alone or in combination with existing treatments.

The initial studies are due to commence in early 2017 with results expected later in the year.

Harry Karelis, chairman, commented:

"Zelda was established to conduct a series of pre-clinical and clinical activities to determine whether positive anecdotal experiences observed in patients in California can be reproduced in a controlled laboratory and clinical setting.

"We are excited to be partnering with the Telethon Kids Institute in the important area of childhood cancer.

"Positive results from these studies have the potential to lay the foundations for improved treatment outcomes and quality of life for cancer patients."

]]>
Mon, 05 Dec 2016 10:40:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169926/zelda-therapeutics-to-work-with-a-leading-medical-research-institute-169926.html
<![CDATA[News - Zelda Therapeutics shares climb following medical cannabis proof of concept study ]]> http://www.proactiveinvestors.com.au/companies/news/169798/zelda-therapeutics-shares-climb-following-medical-cannabis-proof-of-concept-study-169798.html The initial study compared the anti-tumour responses of pure tetrahydrocannabinol (THC) versus the Zelda Therapeutics formulation of THC-rich oil.

The study also compared the potency against a standard chemotherapy drug, Lapatanib.

The study showed that Zelda’s formulation of THC-rich oil was significantly more potent at reducing tumour growth than pure THC and more importantly, was as potent as Lapatanib in reducing tumour growth.

The ultimate aim of the work program is to licence this intellectual property to a major group better resourced to progress into formal human clinical trials in the area of cancer therapy.

As per the company’s business model, Zelda will benefit through structuring deals comprised of up-front payments, milestones and royalties from these licensees.

The U.S. medical cannabis market alone is projected to be valued at over US$6 billion by 2018.

Zelda recently re-listed on the ASX raising $4 million following the finalisation of a reverse take-over.

]]>
Thu, 01 Dec 2016 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169798/zelda-therapeutics-shares-climb-following-medical-cannabis-proof-of-concept-study-169798.html
<![CDATA[News - Zelda Therapeutics’ medical cannabis study results see shares pop ]]> http://www.proactiveinvestors.com.au/companies/news/169729/zelda-therapeutics-medical-cannabis-study-results-see-shares-pop-169729.html Zelda Therapeutics (ASX:ZLD)  has received positive results of its initial proof of concept study into the anti-cancer effects of its medical cannabis formulation.

Results show that Zelda’s formulation of THC-rich oil is significantly more potent at reducing tumour growth than pure THC and equally as potent as a standard chemotherapy drug, Lapatanib in reducing tumour growth.

The positive results provide support for Zelda to continue its program of study evaluating its THC-rich medical cannabis formulations as anti-cancer therapeutics.

Harry Karelis, executive chairman, commented: “We are very excited by the data generated in this preliminary study examining our cannabis extracts in well validated models of human breast cancer. 

“This provides a solid foundation to continue to examine the anti-cancer effects of whole-plant cannabis extracts particularly as a combination therapy for cancer sufferers.”


Recently listed on the ASX

Zelda recently re-listed on the ASX following the finalisation of a reverse take-over.

The company raised the $4 million maximum allowed under its prospectus offering, transitioning Zelda into a publicly listed medical cannabis company.

The funds raised are to continue with pre-clinical research and development activities, fund human clinical trials and expand the management and/or advisory team.

Zelda was spun out of a successful U.S. based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.


Study details

The initial proof of concept study was conducted on behalf of Zelda by world leading cannabis cancer researchers at Complutense University of Madrid.

This initial study compared the anti-tumour responses of pure tetrahydrocannabinol (THC) versus the Zelda Therapeutics formulation of THC-rich oil.

The study also compared the potency against a standard chemotherapy drug, Lapatanib, which is a tyrosine-kinase inhibitor of HER2 and EGFR, both receptors known to play an important role in breast cancer.

The study showed that Zelda’s formulation of THC-rich oil was significantly more potent at reducing tumour growth than pure THC and more importantly, was as potent as Lapatanib in reducing tumour growth.


Study goals

The ultimate aim of the work program is to licence this intellectual property to a major group better resourced to progress into formal human clinical trials in the area of cancer therapy. 

As per the company’s business model, Zelda will benefit through structuring deals comprised of up-front payments, milestones and royalties from these licensees.


Analysis

This initial data is important as it supports the anecdotal experiences already seen in patients in California.

Future studies will examine the potential to significantly increase the anti-cancer effect of traditional chemotherapy drugs and is an exciting opportunity that can not only improve a patient’s quality of life but also potentially extend life expectancy. 

The U.S. medical cannabis market alone is projected to be valued at over US$6 billion by 2018.

Zelda has a strategic focus on the development of treatments for skin conditions, cancer and insomnia.

Shares in Zelda are trading up 32% currently priced at $0.033 compared to its re-listing price of $0.025.

]]>
Wed, 30 Nov 2016 14:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169729/zelda-therapeutics-medical-cannabis-study-results-see-shares-pop-169729.html
<![CDATA[News - Zelda Therapeutics Ltd's board member Mara Gordon becomes a substantial shareholder ]]> http://www.proactiveinvestors.com.au/companies/news/169559/zelda-therapeutics-ltd-s-board-member-mara-gordon-becomes-a-substantial-shareholder-169559.html Zelda Therapeutics Ltd (ASX:ZLD) has received a notice of initial substantial shareholder from Mara Gordon, who holds circa 79.6 million shares for a 11.9% stake.

Gordon is the co-founder of Aunt Zelda’s and Zelda Therapeutics, and specialises in the development of cannabis extract treatment protocols for seriously ill patients in California.


The making of Zelda Therapeutics

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.

]]>
Mon, 28 Nov 2016 09:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169559/zelda-therapeutics-ltd-s-board-member-mara-gordon-becomes-a-substantial-shareholder-169559.html
<![CDATA[News - Zelda Therapeutics Ltd strengthens medical cannabis intellectual portfolio ]]> http://www.proactiveinvestors.com.au/companies/news/169509/zelda-therapeutics-ltd-strengthens-medical-cannabis-intellectual-portfolio-169509.html Zelda Therapeutics Ltd (ASX:ZLD) is focused on medical cannabis, which is becoming recognised worldwide as a natural and effective medicine to treat a growing number of diseases and conditions.

The key for the company is that it was spun out of a US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

Zelda has therefore has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

Now Zelda has further strengthened its intellectual property portfolio, filing a series of international patent applications.

Harry Karelis, executive chairman, commented:

"Our investment in building a solid portfolio of intellectual property is a core part of Zelda’s business model.

"We believe that in time, as the global medicinal cannabis sector continues to expand, that those companies holding proprietary intellectual property positions along with well-respected brands, will attract premium valuations.

"Investors can expect to see Zelda continue to invest in this area."


Patents

Zelda has finalised the lodgement of a series of patent applications concerning certain aspects of its medical cannabis intellectual property across multiple medical indications.

The confirmation of lodgement follows a detailed intellectual property landscape review of the medicinal cannabis field conducted by intellectual property law firm Griffith Hack.

The lodgement of these patent applications provides a significant opportunity for Zelda to build a diversified portfolio of valuable intellectual property as it continues to invest in pre-clinical and clinical research and demonstrate solid data to underpin its patent claims.


Next steps

Zelda will continue to focus on generating novel intellectual property which will be protected through a combination of patents and in-house know-how.

In addition, it is pursuing discussions with groups holding complementary technologies that may have benefit to Zelda either as jointly owned or licensed intellectual property.

]]>
Fri, 25 Nov 2016 10:40:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169509/zelda-therapeutics-ltd-strengthens-medical-cannabis-intellectual-portfolio-169509.html
<![CDATA[News - Zelda Therapeutics Ltd has a new substantial holder ]]> http://www.proactiveinvestors.com.au/companies/news/169428/zelda-therapeutics-ltd-has-a-new-substantial-holder-169428.html Zelda is focused on medical cannabis, which is becoming recognised worldwide as a natural and effective medicine to treat a growing number of diseases and conditions.


The making of Zelda

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.

]]>
Thu, 24 Nov 2016 08:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169428/zelda-therapeutics-ltd-has-a-new-substantial-holder-169428.html
<![CDATA[News - Zelda Therapeutics Ltd hits the ASX boards and trades at a premium ]]> http://www.proactiveinvestors.com.au/companies/news/169294/zelda-therapeutics-ltd-hits-the-asx-boards-and-trades-at-a-premium-169294.html Zelda last traded at $0.027, a 7% premium to the recent $4 million raising.

The company has a tight register, with the top 20 shareholders owning 60% of the stock, (50% escrowed).

Zelda is focused on medical cannabis, and will use the funds raised to continue with pre-clinical research and development activities, fund human clinical trials and expand the management and/or advisory team.

Medical cannabis is becoming recognised worldwide as a natural and effective medicine to treat a growing number of diseases and conditions.


How does medical cannabis work?

Cannabis contains more than 85 types of cannabinoids, the chemical compounds secreted by cannabis flowers.

Cannabinoids bind to receptors in the brain and body, mimicking naturally occurring endocannabinoids.

Different medical effects can be achieved by targeting different receptors, using different types or quantities of cannabinoids.

]]>
Tue, 22 Nov 2016 10:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169294/zelda-therapeutics-ltd-hits-the-asx-boards-and-trades-at-a-premium-169294.html
<![CDATA[News - Zelda Therapeutics Ltd re-lists on ASX with advanced medical cannabis focus ]]> http://www.proactiveinvestors.com.au/companies/news/169216/zelda-therapeutics-ltd-re-lists-on-asx-with-advanced-medical-cannabis-focus-169216.html Zelda Therapeutics Ltd (ASX:ZLD) will hit the ASX boards at the commencement of trade tomorrow, Tuesday 22nd November 2016, following the finalisation of a reverse take-over.

Zelda recently raised the $4 million maximum allowed under its prospectus, transitioning Zelda into a publicly listed medical cannabis company.

The funds raised are to continue with pre-clinical research and development activities, fund human clinical trials and expand the management and/or advisory team.


The making of Zelda

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.


Why Medical cannabis

The U.S. medical cannabis market alone is projected to be valued at over US$6 billion by 2018.

Zelda has a strategic focus on the development of treatments for skin conditions, cancer and insomnia.


Capital structure of Zelda

Shares – Unrestricted: 322,627,649.
Shares - Escrowed 12 months from the date of issue of securities: 111,625,156.
Shares – Escrowed 24 months from re-quotation: 224,374,844.
Unlisted Shares - Escrowed 12 months from the date holders subscribed for convertible notes in Zelda Therapeutics Pty Ltd: 10,500,000.

Total: 669,127,649.

In addition: Options - Escrowed 24 months from re-quotation: 40,000,000.

]]>
Mon, 21 Nov 2016 09:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169216/zelda-therapeutics-ltd-re-lists-on-asx-with-advanced-medical-cannabis-focus-169216.html
<![CDATA[News - Zelda Therapeutics Ltd raises maximum for medical cannabis ahead of ASX listing ]]> http://www.proactiveinvestors.com.au/companies/news/169036/zelda-therapeutics-ltd-raises-maximum-for-medical-cannabis-ahead-of-asx-listing-169036.html Zelda Therapeutics Ltd (ASX:ZLD) has successfully raised the maximum allowed under its prospectus offering, which is $4 million.

A total of 160 million post-consolidation shares will be issued to new investors at $0.025 per share.

The prospectus offering is looking to transition Zelda into a publicly listed medical cannabis company.

The funds raised are to continue with pre-clinical research and development activities, fund human clinical trials and expand the management and/or advisory team. 

The company will now proceed with the formal re-admission process with the Australian Securities Exchange and will provide an update on the indicative listing date in due course.

Zelda, formerly Gleneagle Gold Ltd, has changed its ASX ticker code from GLN to ZLD.


Background

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.

Aunt Zelda’s has a very high profile within the U.S. and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols by the Aunt Zelda’s group.

Zelda will use this information to design a series of Phase 2-ready human clinical trials which the company is confident will be successful given the existing patient experiences and treatment outcomes.


Medical cannabis

The U.S. medical cannabis market is projected to be valued at over US$6 billion by 2018.

Zelda has a strategic focus on the development of treatments for skin conditions, cancer and insomnia.

Zelda’s focus is on relatively low cost, short duration trials in high-value niche indications for maximum value.

This includes:

Observation trials.

- Paediatric glioblastoma (brain tumour); and
- Adult glioblastoma (brain tumour).

Pre-clinical research.

- Breast cancer; and
- Acute wound healing.

Clinical trials.

- Insomnia;
- Acne; and
- Chronic wound healing.

]]>
Wed, 16 Nov 2016 10:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/169036/zelda-therapeutics-ltd-raises-maximum-for-medical-cannabis-ahead-of-asx-listing-169036.html
<![CDATA[News - Zelda Therapeutics Ltd starts countdown to ASX listing ]]> http://www.proactiveinvestors.com.au/companies/news/167971/zelda-therapeutics-ltd-starts-countdown-to-asx-listing-167971.html Zelda Therapeutics Ltd's (ASX:ZLD) transition to being a publically listed medical cannabis focused company is almost complete.

Investor interest has been strong in the new company, with valid subscriptions of over $4 million already received.

Zelda (previously Gleneagle Gold, GLN) expects its shares to be reinstated to the ASX on the 25th November 2016.

Today the ASX granted a waiver from listing rule 14.7 to the extent necessary to permit the company to issue securities, as approved by shareholders at the general meeting held on 25 July 2016.

This is purely a technical issue related to the extended timetable and does not affect any material aspect of the transaction.

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

]]>
Thu, 27 Oct 2016 08:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/167971/zelda-therapeutics-ltd-starts-countdown-to-asx-listing-167971.html
<![CDATA[News - Zelda Therapeutics receives $4M worth of interest ]]> http://www.proactiveinvestors.com.au/companies/news/167263/zelda-therapeutics-receives-4m-worth-of-interest-167263.html Zelda Therapeutics Ltd (ASX:ZLD) has been formed through the reverse-takeover of the previously ASX-listed Gleneagle Gold Ltd.

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

the company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.


Zelda Therapeutics status

Zelda Therapeutics has today issued a supplementary prospectus with the Australian Securities & Investment Commission which extends the offer period by a minimum of one month.

This extension is merely a result of a technical issue related to having shares quoted on the Australian Securities Exchange within three months of the lodgement of the prospectus.

Investor interest has been strong in the new company, with valid subscriptions of over $4 million already received.


ASX listing timing

- Closing Date for the Offers 11 November 2016.
- Dispatch of holding statements 18 November 2016.
- Expected date for Shares to be reinstated to trading on ASX 25 November 2016.


Medical cannabis

The U.S. medical cannabis market is projected to be valued at over US$6 billion by 2018.

Zelda has a strategic focus on the development of treatments for skin conditions, cancer and insomnia.

Zelda’s focus is on relatively low cost, short duration trials in high-value niche indications for maximum value.

This includes:

Observation trials
- Paediatric glioblastoma (brain tumour); and
- Adult glioblastoma (brain tumour).

Pre-clinical research
- Breast cancer; and
- Acute wound healing.

Clinical trials
- Insomnia;
- Acne; and
- Chronic wound healing.

]]>
Wed, 12 Oct 2016 13:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/167263/zelda-therapeutics-receives-4m-worth-of-interest-167263.html
<![CDATA[News - Gleneagle Gold Ltd raises $4M ahead of name change to Zelda Therapeutics Ltd ]]> http://www.proactiveinvestors.com.au/companies/news/166137/gleneagle-gold-ltd-raises-4m-ahead-of-name-change-to-zelda-therapeutics-ltd-71117.html Gleneagle Gold Ltd (ASX:GLN), to be renamed Zelda Therapeutics Ltd, has successfully raised the maximum of $4 million under its prospectus offering which is part of a re-listing.

A total of 160 million post-consolidation shares were issued to new investors at $0.025 per share.

The offer closed early and over-subscribed.

The reverse takeover of Zelda Therapeutics will see the company enter the medical cannabis sector.

Funds raised are to continue with pre-clinical research and development activities, fund human clinical trials and expand the management and advisory team.

The company’s ASX ticker code will change from GLN to ZLD.


Zelda Therapeutics

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

Zelda has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.

Aunt Zelda’s has a very high profile within the U.S. and a growing international profile based on its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols by the Aunt Zelda’s group.

Zelda will use this information to design a series of Phase 2-ready human clinical trials which the company is confident will be successful given the existing patient experiences and treatment outcomes.


Medical cannabis

The U.S. medical cannabis market is projected to be valued at over US$6 billion by 2018.

Zelda has a strategic focus on the development of treatments for skin conditions, cancer and insomnia.

Zelda’s focus is on relatively low cost, short duration trials in high-value niche indications for maximum value.

This includes:

Observation trials
- Paediatric glioblastoma (brain tumour); and
- Adult glioblastoma (brain tumour).

Pre-clinical research
- Breast cancer; and
- Acute wound healing.

Clinical trials
- Insomnia;
- Acne; and
- Chronic wound healing.


ASX re-listing

The company will proceed with the formal re-admission process with the ASX and will provide an update on the indicative listing date in due course.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

]]>
Tue, 20 Sep 2016 13:40:00 +1000 http://www.proactiveinvestors.com.au/companies/news/166137/gleneagle-gold-ltd-raises-4m-ahead-of-name-change-to-zelda-therapeutics-ltd-71117.html
<![CDATA[News - Gleneagle / Zelda Therapeutics Ltd outlines medical cannabis strategy with investors ]]> http://www.proactiveinvestors.com.au/companies/news/165195/gleneagle-zelda-therapeutics-ltd-outlines-medical-cannabis-strategy-with-investors-70266.html Gleneagle Gold Ltd (ASX:GLN) shareholders recently approved the acquisition of Zelda Therapeutics Pty Ltd, a biotechnology company focused on medical cannabis therapies.

Zelda has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This week Dr. Stewart Washer, executive director, joined the Proactive Spotlight CEO Investor Session in Sydney, outlining the company strategy to investors.

ACCESS THE FULL PRESENTATION HERE

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

]]>
Fri, 05 Aug 2016 15:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/165195/gleneagle-zelda-therapeutics-ltd-outlines-medical-cannabis-strategy-with-investors-70266.html
<![CDATA[News - Gleneagle Gold Ltd brings medical cannabis to Proactive's CEO Spotlight Session ]]> http://www.proactiveinvestors.com.au/companies/news/136472/gleneagle-gold-ltd-brings-medical-cannabis-to-proactives-ceo-spotlight-session-69865.html Gleneagle Gold Ltd (ASX:GLN) is in the final stages of its transition into the medical cannabis sector through the reverse takeover of Zelda Therapeutics.

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

Zelda has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.

Aunt Zelda’s has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols by the Aunt Zelda’s group.

Zelda will use this information to design a series of Phase 2-ready human clinical trials which the company is confident will be successful given the existing patient experiences and treatment outcomes.

 

Find out more from Dr. Stewart Washer, executive director, at Proactive's Spotlight CEO Sessions in Sydney in August 2016.

REGISTER HERE, CLICK ON LINK: Sydney Investor Sessions, Wednesday, 3rd August

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 19 Jul 2016 09:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/136472/gleneagle-gold-ltd-brings-medical-cannabis-to-proactives-ceo-spotlight-session-69865.html
<![CDATA[News - Gleneagle Gold Ltd receives notice of initial substantial holder ]]> http://www.proactiveinvestors.com.au/companies/news/136471/gleneagle-gold-ltd-receives-notice-of-initial-substantial-holder-69713.html Gleneagle Gold Ltd (ASX:GLN) continues to advance towards re-listing on the ASX as a medical cannabis company.

The company has now received a notice of initial substantial holder from Gemelli Nominees Pty Ltd, which holds 33.3 million shares, or around 5.5%.

Gleneagle is in the final steps of the reverse takeover of Zelda Therapeutics, a California-based biotechnology company.

Zelda is a biotechnology company that was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company will host its general meeting on the 25th July 2016 in Perth, where shareholders will vote on the significant change to the nature and scale of its activities.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 11 Jul 2016 10:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/136471/gleneagle-gold-ltd-receives-notice-of-initial-substantial-holder-69713.html
<![CDATA[News - Gleneagle Gold Ltd to consolidate shares ahead of medical cannabis transition ]]> http://www.proactiveinvestors.com.au/companies/news/136470/gleneagle-gold-ltd-to-consolidate-shares-ahead-of-medical-cannabis-transition-69502.html Gleneagle Gold Ltd (ASX:GLN) continues to advance towards re-listing on the ASX as a medical cannabis company.

The company is now undertaking a consolidation of 5 shares into 1, which will reduce the total number of shares on issue to 120.6 million.

The company will host its general meeting on the 25th July 2016 in Perth, where shareholders will vote on the significant change to the nature and scale of its activities.

Gleneagle is in the final steps of the reverse takeover of Zelda Therapeutics, a California-based biotechnology company.

Zelda is a biotechnology company that was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

Zelda has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 29 Jun 2016 09:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/136470/gleneagle-gold-ltd-to-consolidate-shares-ahead-of-medical-cannabis-transition-69502.html
<![CDATA[News - Gleneagle Gold Ltd outlines final timeline to medicinal cannabis transition ]]> http://www.proactiveinvestors.com.au/companies/news/136469/gleneagle-gold-ltd-outlines-final-timeline-to-medicinal-cannabis-transition-69353.html Gleneagle Gold Ltd (ASX:GLN) is well-advanced in its transition into the medical cannabis sector, as it progresses the  reverse takeover of Zelda Therapeutics, a California-based biotechnology company.

The company will host its general meeting on the 25th July 2016 in Perth, where shareholders will vote on the significant change to the nature and scale of its activities.

Zelda is a biotechnology company that was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

Zelda has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

This human data has been generated over several years by the Aunt Zelda’s group.

Aunt Zelda’s has a very high profile within the U.S. and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols by the Aunt Zelda’s group.

Zelda will use this information to design a series of Phase 2-ready human clinical trials that have a high probability of success given the existing patient experiences and treatment outcomes


Next steps post acquisition

- Expand the management team;
- Continue pre-clinical research and development activities in Spain and eventually Australia; and
- Plan and fund the commencement of human clinical trials in Canada and eventually Australia.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 22 Jun 2016 09:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/136469/gleneagle-gold-ltd-outlines-final-timeline-to-medicinal-cannabis-transition-69353.html
<![CDATA[News - Gleneagle Gold Ltd completes Pre-IPO Capital Raise ]]> http://www.proactiveinvestors.com.au/companies/news/136468/gleneagle-gold-ltd-completes-pre-ipo-capital-raise-68919.html Gleneagle Gold Ltd (ASX:GLN) is well-advanced in its transition into the medical cannabis sector, as it progresses the  reverse takeover of Zelda Therapeutics, a California-based biotechnology company.

Zelda has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.

Zelda has now raised AU$1.05 million via the issue of convertible notes, ahead of its proposed acquisition by Gleneagle and listing on the Australian Securities Exchange.

These funds were raised from certain professional and sophisticated investors, including cornerstone investor, the Merchant Opportunities Fund.

Harry Karelis, chairman for Zelda, commented:

“We are delighted that Zelda has received such strong support from key investor, Merchant Group highlighting the significant opportunity to be a leader in this fast moving and emerging sector.

"Our focus is clearly on designing and conducting world-class trials to generate the clinical data demanded by regulators.

"Our activities should help to breakdown the barriers to providing increasing access to patients in need.”


Note details

Under the terms of the issue, the convertible notes automatically convert into ordinary shares at a 20% discount to the prospectus capital raising price as part of the recompliance listing process.

The notes form part of a broader equity raising that will fund the company’s planned clinical trial program and research initiatives, including key clinical trials in sleep disorders (insomnia) and certain dermatology indications (acne).

Funding will also be for pre-clinical research in certain cancer indications with leading global groups including Complutense University Madrid.


Growth strategy

Zelda's growth strategy will be focused on developing existing products.

This means completing phase 2 clinical trials in dermatology indications and insomnia. It also means completing Spanish pre‐clinical research in cancer.

Zelda will then out‐license products with successful phase 2 results.

The secondary growth strategy will be expanding trials into new diseases and territories, which may come through partnerships.

A broad range of medical indications have been shown to be alleviated by medical cannabis

Zelda will also be looking at opportunities to merge and/or acquire as well as in-license new extracts for clinical testing and validation.


Strategic partnerships

Zelda has secured a number of partnerships with leaders in cannabis medicine.

It has an exclusive patient data access agreement in place with Aunt Zelda’s, a pioneering, data‐driven developer of cannabis‐based medicines.

A manufacturing agreement is in place with AusCann, an Australian company working with one of the largest medical cannabis groups in the world to supply clinical trial material.

Zelda has a partnership with New Frontier, the leading cannabis data company based in the U.S. for data sharing.

Zelda also has exclusive access to CDRMed for clinical trial use, which is software which creates optimal formulations of medicinal cannabis based on the Aunt Zelda’s database.

Finally, a partnership is also in place with the prestigious Complutense University Madrid for pre‐clinical research in cancer.


Analysis

The application of medical cannabis in modern medicine is still growing and represents a diverse global opportunity.

Partnerships with New Frontier, CDRMed and Aunt Zelda could provide for the acceleration to phase 2 efficacy clinical trials.

Today's news shows strong investment support into the sector.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 30 May 2016 13:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/136468/gleneagle-gold-ltd-completes-pre-ipo-capital-raise-68919.html
<![CDATA[News - Gleneagle Gold Ltd is well-advanced in transition to medical cannabis ]]> http://www.proactiveinvestors.com.au/companies/news/136467/gleneagle-gold-ltd-is-well-advanced-in-transition-to-medical-cannabis-68468.html Gleneagle Gold Ltd (ASX:GLN) is well-advanced in its transition into the medical cannabis sector, as it progresses the  reverse takeover of Zelda Therapeutics, a California-based biotechnology company.

Gleneagle has issued 1.6 billion shares to acquire Zelda.

Gleneagle now plans to issue a prospectus and change its name to Zelda Therapeutics Limited.

Zelda has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.

This human data has been generated over several years by a California-based group, Caziwell Inc., which operates the Aunt Zelda’s group.

Zelda will use this information to design a series of phase 2-ready human clinical trials.

Zelda sees a strong probability of success given the existing patient data and experiences it has access to.

Road to commercialisation

Zelda has a clear commercialisation strategy, which begins with pre-clinical and clinical studies in-house.

The end goal is to out-license or partner with leading pharmaceutical and biotechnology companies for phase 3 trials and marketing.

The out-licensing revenue model consists of up-front and milestone payments and also royalties from marketed products.


Growth strategy

Zelda's growth strategy will be focused on developing existing products.

This means completing phase 2 clinical trials in dermatology indications and insomnia. It also means completing Spanish pre‐clinical research in cancer.

Zelda will then out‐license products with successful phase 2 results.

The secondary growth strategy will be expanding trials into new diseases and territories, which may come through partnerships.

A broad range of medical indications have been shown to be alleviated by medical cannabis

Zelda will also be looking at opportunities to merge and/or acquire as well as in-license new extracts for clinical testing and validation.


Strategic partnerships

Zelda has secured a number of partnerships with leaders in cannabis medicine.

It has an exclusive patient data access agreement in place with Aunt Zelda’s, a pioneering, data‐driven developer of cannabis‐based medicines.

A manufacturing agreement is in place with AusCann, an Australian company working with one of the largest medical cannabis groups in the world to supply clinical trial material.

Zelda has a partnership with New Frontier, the leading cannabis data company based in the U.S. for data sharing.

Zelda also has exclusive access to CDRMed for clinical trial use, which is software which creates optimal formulations of medicinal cannabis based on the Aunt Zelda’s database.

Finally, a partnership is also in place with the prestigious Complutense University Madrid for pre‐clinical research in cancer.


News flow pipeline

Pending a successful reverse takeover, the company has the following news flow pipeline:

- Commencement of pre‐clinical research in human breast cancer via Complutense University Madrid;
- Commencement of clinical trials in wound care and sleep disorders;
- Pre‐clinical trial results in cancer;
- Clinical trial results from acne, insomnia and wound trials;
- Commencement of observational trials in cancer; and
- Signing of partner for clinical trials in sleep and dermatology applications.

Highly active investment into the sector

Five companies in the US biotechnology sector completed 17 capital raises for a total of $217.4 million in 2015.

GW Pharmaceuticals (NasdaqGM:GWPH) secondary offering of American Depository Shares raised $206.1 million, with the company having a current market cap of circa US$1.6 billion.

NEMUS Bioscience (OTCQB:NMUS) raised a total of $7.2 million, including $5.0 million in its largest raise.

Axim Biotechnologies (OTCQB:AXIM) acquired Can Chew License for CanChew® gum, a unique patented controlled-release cannabinoid-infused chewing gum in 2015.


Analysis

The application of medical cannabis in modern medicine is still growing and represents a diverse global opportunity.

Partnerships with New Frontier, CDRMed and Aunt Zelda could provide for the acceleration to phase 2 efficacy clinical trials.

Zelda has an active news flow pipeline with multiple near term share price catalysts.

With the Zelda valuation <$10 million, this provides material upside potential for incoming investors given median market capitalisation of Phase 2 ready biotechs listed on ASX is circa $50 million.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 06 May 2016 08:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/136467/gleneagle-gold-ltd-is-well-advanced-in-transition-to-medical-cannabis-68468.html
<![CDATA[News - Gleneagle: Dr Noah Federman joins Zelda’s scientific advisory board ]]> http://www.proactiveinvestors.com.au/companies/news/136466/gleneagle-dr-noah-federman-joins-zeldas-scientific-advisory-board-67288.html Gleneagle Gold (ASX:GLN) has positioned itself at the forefront of the medical cannabis sector, after recently entering into an agreement in relation to acquiring 100% of the issued capital of Zelda Therapeutics Pty Ltd.

Zelda has now appointed oncologist and physician scientist, Dr Noah Federman, to its Scientific Advisory Board.

Dr Federman holds extensive clinical oncology experience specialising in treating children with aggressive cancers.

His knowledge and experience in the oncology field will be highly valuable for developing rigorous medical cannabis clinical trials in cancer.

The appointment signals the strong level of medical and scientific support for Zelda’s strategy to validate the efficacy of medical cannabis in key indications.

Harry Karelis, chairman for Zelda, commented:

“Zelda is now clearly positioned as a key thought-leader globally in the medical cannabis space and with numerous governments legislating to allow medical cannabis, most recently in Australia, we are uniquely placed through our relationships to accelerate the scientific understanding and clinical benefits of medical cannabis.”

Dr Federman added:

"I have been aware of Mara Gordon (Zelda co-founder) and her activities for some time and have witnessed first-hand the improvement in the quality of life for my patients from her deep knowledge of the biological effects of medical cannabis.

"Focusing on robust clinical trials to show statistically significant outcomes is crucial to validating the potential of medical cannabis to provide patients in need with new treatment options.”


Zelda's Scientific Advisory Board also includes:

- Dr Joe Goldstrich: An experienced specialist and physician with extensive knowledge in the use of medical cannabis to treat a variety of conditions.

- Professor Manuel Guzman: Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death.

- Dr Cristina Sanchez: Assistant Professor at Complutense University, Madrid Spain and specialist in the area of lipid signalling, including cannabinoids in an oncology setting Dr Donald Abrams - a cancer and integrative medicine specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion and Chief of Haematology and Oncology at San Francisco General Hospital.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

]]>
Wed, 02 Mar 2016 10:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/136466/gleneagle-dr-noah-federman-joins-zeldas-scientific-advisory-board-67288.html
<![CDATA[News - Gleneagle Gold: Zelda Therapeutics Pty Ltd appoints Dr Joe Goldstrich ]]> http://www.proactiveinvestors.com.au/companies/news/136465/gleneagle-gold-zelda-therapeutics-pty-ltd-appoints-dr-joe-goldstrich-66926.html Gleneagle Gold (ASX:GLN) has positioned itself at the forefront of the medical cannabis sector, after entering into an agreement to acquire 100% of the issued capital of Zelda Therapeutics Pty Ltd.

Zelda has now appointed medical clinician, Dr Joe Goldstrich, to the company’s Scientific Advisory Board, with immediate effect.

Dr Goldstrich holds over 40 years of clinical medicine experience, including caring for and evaluating thousands of patients receiving medicinal cannabis.

His knowledge and experience in the US medical cannabis industry will be instrumental in shaping Zelda’s rigorous scientific research and clinical trials.

Harry Karelis, Zelda chairman, commented:

"We are honoured to have a clinician of Dr Goldstrich's calibre and experience joining the Zelda team.

"With a medical career spanning over 40 years and his evidence-based evaluations of the benefits that thousands of patients receive from medical cannabis treatments, his guidance will be instrumental in helping to place Zelda at the forefront of cannabis-based medicines."

Dr Joe Goldstrich, added:

“Whilst the medical cannabis industry is well established in the US and Europe, the medicine is still wildly under-researched.

"It is for this reason I am delighted to join the Scientific Advisory Board of Zelda Therapeutics as they look to validate the use of medical cannabis in treating a variety of ailments and serious illnesses through extensive scientific research and clinical trials.”


Other members of the Scientific Advisory Board include

Professor Manuel Guzman: Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death.

Dr Cristina Sanchez: Assistant Professor at Complutense University, Madrid Spain and specialist in the area of lipid signaling, including cannabinoids in an oncology setting.

Dr Donald Abrams: A cancer and integrative medicine specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion and Chief of Haematology and Oncology at San Francisco General Hospital.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

]]>
Tue, 09 Feb 2016 13:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/136465/gleneagle-gold-zelda-therapeutics-pty-ltd-appoints-dr-joe-goldstrich-66926.html
<![CDATA[News - Gleneagle talks medical cannabis ambitions in Proactive Q&A Sessions™ ]]> http://www.proactiveinvestors.com.au/companies/news/136464/gleneagle-talks-medical-cannabis-ambitions-in-proactive-qa-sessions-66622.html Gleneagle (ASX:GLN) has positioned itself at the forefront of the medical cannabis sector, after recently entering into an agreement in relation to acquiring 100% of the issued capital of Zelda Therapeutics Pty Ltd.

Zelda is leveraging its close relationship with established California based medical cannabis company Aunt Zelda’s.

Aunt Zelda’s has a significant database of patient records indicating solid anecdotal evidence for treating a variety of ailments using protocols and formulations developed by Aunt Zelda’s over several years.

Zelda seeks to fund clinical trials aimed at validating this anecdotal evidence in controlled conditions initially aiming for topical treatment for wound healing, eczema, post-burn itch, acne and certain cancers.

We are joined by Harry Karelis, chairman, Zelda Therapeutics, in the Proactive Q&A Sessions™.


PROACTIVE INVESTORS: Welcome Harry.


First of all, can you outline the intellectual property Zelda either directly holds or has access to, and how is this unique to other companies in the medical cannabis sector?

Harry Karelis: The founders of Zelda have taken a very considered approach to the global medical cannabis sector and spent several months learning about the sector, speaking with many different players in the ecosystem and identifying opportunities that make sense for investors.

We are taking a long term approach to one of the fastest growing sectors in the world and seeking early-mover advantages.

This culminated in identifying a gap in the market in terms of hard, clinical data where there are not more than a handful of companies globally that have approved, cannabinoid-based medicines.

These companies appear to be highly valued by investors and given our backgrounds in the life sciences sector, our knowledge and experience has guided Zelda towards obtaining an exclusive global licence to a set of actual human data via Aunt Zelda’s in California.

This potentially gives us a 10 year head-start over a typical biotech start-up company.

Our sole focus is on converting this anecdotal data into clinically validated data via conducting a series of clinical trials in a variety of indications over time.

We have built a global network of relationships both formal and informal that we will use to accelerate Zelda’s progress which we think is a fairly unique proposition for investors.


A key milestone for Zelda is to fund clinical trials aimed at validating anecdotal evidence. What is an estimate on costs, potential timeline to results and where could this be conducted?

Harry Karelis: The beauty of our business plan is that we already have tremendous insights into what formulations, and importantly what protocols (what to give, how much to give and when to give it) seem to have therapeutic benefit in humans.

This means we can basically skip the lengthy and costly discovery and pre-clinical phases of your typical biotech company.

We have deliberately focused on topically-based trials to start with – that is, applying cannabinoid-based creams to the skin and focused on skin-based conditions.

These are significantly less costly and less complicated than systemic trials of new drugs.

We expect that these trials will be relatively short duration in nature – we are talking a few months and as such relatively inexpensive to conduct with all activities to be out-sourced to professional contract research organisations.

We are hopeful to have a series of trials underway generating regular results over the course of the next 12-24 months.

Positive results combined with creating new intellectual property will open doors to partnerships with third parties and help generate license and milestone fees and ongoing royalties where we choose to work with larger groups.

Working with acknowledged leaders in their respective fields also helps raise our profile amongst the bio-pharmaceutical industry.


Looking forward, how will Zelda protect its intellectual property, and is there a patent structure you will follow?

Harry Karelis: Intellectual property (IP) is the heart of what a biotech company is about especially if you want to maximise your value creation.

We are working with one of Australia’s leading intellectual property firms to ensure that everything we do conforms with international expectations of the regulators and the bio-pharmaceutical sector.

It is not just about lodging a patent over a discovery it is about having a long term IP strategy that incorporates global “landscape” reviews helping to identify areas of interest and opportunities for Zelda to focus on those areas, licensing agreements, royalty arrangements, ensuring all confidentiality and employment agreements are water-tight to minimise “IP leakage”.

Everything we do will work within this over-riding IP strategy and philosophy.


What has been the current interest and investor appetite to provide funding for these trials?

Harry Karelis: At this stage, Zelda is a private company that has been supported by a small group of sophisticated investors based in several parts of the world that have had a greater exposure and understanding of the sector.

These investors recognise the potential of Zelda.

This has allowed Zelda to build its strong global network, secure the core licence and prepare the company for its next round of funding which is now being addressed through the proposed transaction with Gleneagle Gold.


Where could an investor source more knowledge on how to potentially invest in Zelda?

Harry Karelis: I would encourage investors to visit www.zeldatherapeutics.com and register their interest so that a prospectus can be sent to them when complete in early 2016.

Alternatively, if an investor qualifies as a “sophisticated investor” they are able to invest directly into Zelda now as part of a pre-deal convertible note issue.


Finally, can you outline steps that would need to be achieved to move from the current agreement to a new entity listed on the ASX?

Harry Karelis: This transaction will result in a significant change to the nature and scale of Gleneagle’s activities and as such will require shareholders’ approval and will also require the company to re-comply with Chapters 1 and 2 of the ASX Listing Rules.

This means we will be lodging a full form prospectus to raise at least $3 million after Gleneagle Shareholders vote on the transaction in early 2016.

A Notice of Meeting will be despatched in coming weeks with the Gleneagle shareholder meeting to be held roughly four weeks later.

Following a successful capital raising Gleneagle will change its name to Zelda Therapeutics Ltd – at this stage likely to be in March 2016.


PROACTIVE INVESTORS: Thank-you Harry.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

]]>
Tue, 19 Jan 2016 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/136464/gleneagle-talks-medical-cannabis-ambitions-in-proactive-qa-sessions-66622.html
<![CDATA[News - Gleneagle talks medicinal cannabis transition in Proactive Q&A Sessions™ ]]> http://www.proactiveinvestors.com.au/companies/news/136463/gleneagle-talks-medicinal-cannabis-transition-in-proactive-qa-sessions-66063.html Gleneagle Gold (ASX:GLN) has positioned itself to transition into the medical cannabis sector after entering into an agreement in relation to acquiring 100% of the issued capital of Zelda Therapeutics Pty Ltd.

Zelda has been established to focus on funding clinical trials incorporating medicinal cannabis formulations and protocols developed over the past few years by California-based group Aunt Zelda’s in treating >500 patients.

A pipeline of Phase 2 ready clinical trials helps de-risk the opportunity.

To discuss the transition, we are joined exclusively by Harry Karelis, chairman, Zelda Therapeutics, in Proactive Q&A Sessions™.


PROACTIVE INVESTORS: Welcome Harry.


What would the acquisition of Zelda mean for existing Gleneagle shareholders, and what potential could new shareholders expect?

Harry Karelis: The medical cannabis sector is one of the fastest growing sectors globally and Zelda provides a relatively unique, high quality exposure to the sector.

This acquisition gives an opportunity for existing Gleneagle shareholders, and is also likely to attract new investors, which will fund the development of the company.

The proposed backdoor listing will fast-track its development and have it on track to be commencing trials in 2016 initially for skin-based conditions such as eczema, acne and a condition known as post-burn itch.

We will be conducting some pre-clinical research with the world’s best cancer cannabis researchers, with other relationships with key opinion leaders are pending.


Who is Zelda, and what does it control?

Harry Karelis: The founders of Zelda identified the opportunity of medical cannabis, by conducting clinical trials around an extensive set of human data based formulations and treatment protocols developed by a California-based group over several years.

Whilst Zelda is based in Perth, it is globally connected with some of the world’s most respected medical cannabis researchers and clinicians.

There is tremendous anecdotal evidence that cannabis has a role to play in the treatment of a range of illnesses the missing link is formal clinical trial data and related intellectual property in a form acceptable by regulators such as the FDA & TGA and the bio-pharmaceutical industry.

The team behind Zelda’s are all seasoned executives with multi-decade experiences in the life-sciences, capital markets and research sectors.

This experience has helped guide us in formulating Zelda’s focus and objectives and identify priority areas of interest and manage our risk by constructing a pipeline of Phase 2 ready projects that address a large commercial market, are relatively inexpensive to run and are relatively short duration.

Overlaid with the existing human data we have access to that already demonstrated the efficacy in humans, we have initially focused our clinical trial program on skin based conditions such as eczema, acne and wound healing using formulations and protocols that have already demonstrated success.

In addition, we will also conduct some pre-clinical research in the area of cancer with one of the world’s leading academic groups in Madrid.  


Can you outline consideration for the deal, and where would you and current directors of Zelda be positioned in the new entity?

Harry Karelis: Gleneagle will be acquiring 100% of the issued capital of Zelda in an all-scrip deal.

No money is being taken off the table by the Zelda vendors.

The Zelda directors are all founders and as such retain a sizable shareholding aligning interests with all Gleneagle/Zelda shareholders.

These shareholdings will be escrowed for two years and everybody is focused on successfully implementing its business objectives.


Moving on the clinical data of Zelda, how could the existing human data be validated?

Harry Karelis: The main aspect that differentiates Zelda from other groups in the medical cannabis space is our exclusive, global access to an extensive set of patient data.

This data has been generated over several years by the Aunt Zelda’s group in California - founded by Ms Mara Gordon who is a founding director of Zelda.

This group has adopted a very rigorous approach to patient intake, formulation, dosing and the often overlooked and critical treatment protocols.

That is, what to take and when to take it.

Zelda will take that data, prioritise the areas of interest and then work with professional Clinical Research Organisations (CRO’s) who will design and run appropriate trials using industry standard methodology and generate results in a form acceptable to the regulators.

We will engage across multiple-sites in jurisdictions such as Spain, Australia, the U.S. and Canada.

At the same time, we are working with one of Australia’s leading intellectual property firms, Griffith Hack, to ensure that any novel intellectual property is identified and secured.


What intellectual property data does Zelda hold, and can you take us through steps which would ultimately lead to monetisation?

Harry Karelis: The initial intellectual property revolves around our licence to the Aunt Zelda’s data coupled with our human resources and our global linkages.

Combined, these form the core proposition that is Zelda Therapeutics.

The key executives and directors have extensive experience in monetising intellectual property and have existing linkages and relationships within the global bio-pharmaceutical sector.

There is a fairly well established process to generate returns from solid clinical data and industry standard deal terms around up-front, milestone and royalty payments.

Think of Zelda as a bio-pharmaceutical company that has a 10 year head start given its products have already been shown to work in humans.


Finally, can you outline steps that would need to be achieved to move from the current agreement to a new entity listed on the ASX?

Harry Karelis: This transaction will result in a significant change to the nature and scale of Gleneagle’s activities and as such will require shareholders’ approval and will also require the company to re-comply with Chapters 1 and 2 of the ASX Listing Rules.

Steps we would need to take would be shareholders voting in favour of the transaction, then lodging a full form prospectus to raise at least $3 million.

A Notice of Meeting will be despatched in coming weeks with the Gleneagle shareholder meeting to be held roughly four weeks later.

The final step post a successful capital raising, is that Gleneagle will change its name to Zelda Therapeutics Ltd, with timing likely to be in March 2016.


PROACTIVE INVESTORS: Thank-you Harry.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 09 Dec 2015 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/136463/gleneagle-talks-medicinal-cannabis-transition-in-proactive-qa-sessions-66063.html
<![CDATA[News - Gleneagle Gold has acquisition to reveal ]]> http://www.proactiveinvestors.com.au/companies/news/136462/gleneagle-gold-has-acquisition-to-reveal-66015.html Gleneagle Gold (ASX:GLN) has been granted a trading halt by the ASX, pending details of an acquisition.

Gleneagle added that the proposed acquisition is outside of its existing principal activity.

The halt will remain in place until the opening of trade on Wednesday 9th December 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 07 Dec 2015 12:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/136462/gleneagle-gold-has-acquisition-to-reveal-66015.html
<![CDATA[News - Gleneagle Gold, International Gold top ASX gainers by midday ]]> http://www.proactiveinvestors.com.au/companies/news/136461/gleneagle-gold-international-gold-top-asx-gainers-by-midday-63152.html Friday’s leading ASX % Gainers at midday.

NameCodeLastChangeVolume Gleneagle Gold ASX:GLN $0.003 50% 2,915,472 International Goldfields ASX:IGS $0.003 50% 750,000 Venture Minerals ASX:VMS $0.034 47.8% 890,372 GB Energy ASX:GBX $0.007 40% 2,200,000 East Africa Resources ASX:EAF $0.004 33.3% 1,879,607 Pacifico Minerals ASX:PMY $0.016 33.3% 1,319,737 ADX Energy ASX:ADX $0.004 33.3% 129,797 Bass Strait Oil Company ASX:BAS $0.004 33.3% 1,280,000 Antipa Minerals ASX:AZY $0.014 27.3% 18,102,392 Vector Resources ASX:VEC $0.014 27.3% 282,000

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 26 Jun 2015 13:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/136461/gleneagle-gold-international-gold-top-asx-gainers-by-midday-63152.html